Literature DB >> 23369103

Stem cell transplantation after reduced-intensity conditioning for sickle cell disease.

Susanne Matthes-Martin1, Anita Lawitschka, Gerhard Fritsch, Thomas Lion, Brigitte Grimm, Sabine Breuer, Heidrun Boztug, Susanne Karlhuber, Wolfgang Holter, Christina Peters, Milen Minkov.   

Abstract

Sickle cell disease (SCD) is still associated with substantial morbidity and reduced life expectancy. Disease-related mortality rises to 14% in adolescents and young adults. Overall and disease-free survival following haematopoietic stem cell transplantation (HSCT) is 90% and 95%, respectively. To reduce transplant-associated late effects, the feasibility of a highly immunosuppressive reduced-intensity conditioning (RIC) regimen was explored in children with SCD and a matched sibling donor. Eight patients (median age, 9 yr) and symptomatic SCD were included. The conditioning regimen consisted of fludarabine, melphalan and either thiotepa or total lymphoid irradiation plus antithymocyte globuline or alemtuzumab. The graft was bone marrow in seven and cord blood in one case. The conditioning regimen was well tolerated and no severe infectious complications occurred. All patients displayed mixed chimaerism on day +28. After a median follow-up of 4 yr, 3/8 patients have mixed leucocyte chimaerism and 8/8 patients have 100% donor erythropoiesis. HSCT from matched sibling donors following a RIC regimen was well tolerated and resulted in cure in all patients studied. If confirmed in larger patient cohorts, these observations will have important implications for the indications of HSCT in children with SCD.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Year:  2013        PMID: 23369103     DOI: 10.1111/ejh.12082

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  The case for HLA-identical sibling hematopoietic stem cell transplantation in children with symptomatic sickle cell anemia.

Authors:  Courtney D Fitzhugh; Mark C Walters
Journal:  Blood Adv       Date:  2017-12-08

2.  Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major.

Authors:  Yongliang Huo; Jonathan R Lockhart; Shanrun Liu; Suean Fontenard; Mike Berlett; Thomas M Ryan
Journal:  Blood Adv       Date:  2017-11-28

3.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

4.  Alternative donor hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Andrew L Gilman; Michael J Eckrich; Stacy Epstein; Carrie Barnhart; Mark Cannon; Tracy Fukes; Michelle Hyland; Krishna Shah; Darci Grochowski; Elizabeth Champion; Anastasia Ivanova
Journal:  Blood Adv       Date:  2017-06-28

Review 5.  Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.

Authors:  Hitomi Hosoya; Jeffrey Levine; Peter Abt; David Henry; David L Porter; Saar Gill
Journal:  Blood Adv       Date:  2018-03-13

Review 6.  Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.

Authors:  Courtney D Fitzhugh; Allistair A Abraham; John F Tisdale; Matthew M Hsieh
Journal:  Hematol Oncol Clin North Am       Date:  2014-09-29       Impact factor: 3.722

7.  Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.

Authors:  Emanuele Angelucci; Susanne Matthes-Martin; Donatella Baronciani; Françoise Bernaudin; Sonia Bonanomi; Maria Domenica Cappellini; Jean-Hugues Dalle; Paolo Di Bartolomeo; Cristina Díaz de Heredia; Roswitha Dickerhoff; Claudio Giardini; Eliane Gluckman; Ayad Achmed Hussein; Naynesh Kamani; Milen Minkov; Franco Locatelli; Vanderson Rocha; Petr Sedlacek; Frans Smiers; Isabelle Thuret; Isaac Yaniv; Marina Cavazzana; Christina Peters
Journal:  Haematologica       Date:  2014-05       Impact factor: 9.941

8.  Quality of life.

Authors:  Samuel Charache
Journal:  Rev Bras Hematol Hemoter       Date:  2013

Review 9.  Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015.

Authors:  A Sureda; P Bader; S Cesaro; P Dreger; R F Duarte; C Dufour; J H F Falkenburg; D Farge-Bancel; A Gennery; N Kröger; F Lanza; J C Marsh; A Nagler; C Peters; A Velardi; M Mohty; A Madrigal
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

10.  A trial of unrelated donor marrow transplantation for children with severe sickle cell disease.

Authors:  Shalini Shenoy; Mary Eapen; Julie A Panepinto; Brent R Logan; Juan Wu; Allistair Abraham; Joel Brochstein; Sonali Chaudhury; Kamar Godder; Ann E Haight; Kimberly A Kasow; Kathryn Leung; Martin Andreansky; Monica Bhatia; Jignesh Dalal; Hilary Haines; Jennifer Jaroscak; Hillard M Lazarus; John E Levine; Lakshmanan Krishnamurti; David Margolis; Gail C Megason; Lolie C Yu; Michael A Pulsipher; Iris Gersten; Nancy DiFronzo; Mary M Horowitz; Mark C Walters; Naynesh Kamani
Journal:  Blood       Date:  2016-09-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.